HLA-DR restricted peptide candidates for bee venom immunotherapy

Journal of Immunology

Volumn 164, Issue 6, 2000, Pages 3177-3184

  Texier, Catherine ^a   Pouvelle, Sandra ^a   Busson, Marc ^b   Hervé, Mireille ^a   Charron, Dominique ^b   Ménez, André ^a   Maillère, Bernard ^a  

^a CEA SACLAY   (France)

^b SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BEE VENOM; HLA DR ANTIGEN;

ALLERGY; AMINO ACID SEQUENCE; ARTICLE; BEE STING; HUMAN; HUMAN CELL; IMMUNOTHERAPY; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0034654312     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.164.6.3177     Document Type: Article

References (44)

1. Jutel, M., W. J. Pichler, D. Skrbic, A. Urwyler, C. Dahinden, and U. R. Muller. 1995. Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-γ secretion in specific allergen-stimulated T cell cultures. J. Immunol. 154:4187.
2. 2 in bee venom immunotherapy and recovery by IL-2 and IL-15 in vitro. J. Clin. Invest. 98:1676.
3. Ferreira, F., C. Ebner, B. Kramer, G. Casari, P. Briza, A. J. Kungl, R. Grimm, B. Jahn-Schmid, H. Breiteneder, D. Kraft. et al. 1998. Modulation of IgE reactivity of allergens by site-directed mutagenesis: potential use of hypoallergenic variants for immunotherapy. FASEB J. 12:231.
4. Takai, T., T. Yokota, M. Yasue, C. Nishiyama, T. Yuuki, A, Mori, H. Okudaira, and Y. Okumura. 1997. Engineering of the major house dust mile allergen Der f 2 for allergen-specific immunotherapy. Nat. Biotechnol. 15:754.
5. Smith, A. M., M. D. Chapman, E. A. Taketomi, T. A. Platts-Mills, and S. S. Sung. 1998. Recombinant allergens for immunotherapy: a Der p 2 variant with reduced IgE reactivity retains T-cell epitopes. J. Allergy Clin. Immunol. 101:423.
6. Norman, P. S., J. L. Ohman, Jr., A. A. Long, P. S. Creticos, M. A. Gefter, Z. Snaked, R. A. Wood, P. A. Eggleston, K. B. Hafner, P. Rao, et al. 1996. Treatment of cat allergy with T-cell reactive peplides. Am. J. Respir. Crit. Care Med. 154:1623.
7. 2 induces specific T-cell anergy in patients allergic to bee venom. J. Allergy Clin. Immunol. 101:747.
8. Counsell, C. M., J. F. Bond, J. L. Ohman, Jr., J. L. Greenstein, and R. D. Garman. 1996. Definition of the human T-cell epitopes of Feld 1, the major allergen of the domestic cat. J. Allergy Clin. Immunol. 98:884.
9. 2. J. Immunol. 150:3582.
10. 2 epitopes using short or long overlapping synthetic peptides: interest for specific immunotherapy. Clin. Exp. Allergy 27:1016.
11. Rammensee, H. G., T. Friede, and S. Stevanoviic. 1995. MHC ligands and peptide motifs: first listing. Immunogenetics 41:178.
12. Jardetzky, T. S., J. C. Gorga, R. Busch, J. Rothbard, J. L. Strominger, and D. C. Wiley. 1990. Peptide binding to HLA-DR1: a peptide with most residues substituted to alanine retains MHC binding. EMBO J. 9:1797.
13. Herve, M., B. Maillere, G. Mourier, C. Texier, S. Leroy, and A. Menez. 1997. On the immunogenic properties of retro-inverso peptides. Total retro-inversion of T-cell epitopes causes a loss of binding to MHC II molecules. Mol. Immunol. 34:157.
14. Stern, L. J., J. H. Brown, T. S. Jardetzky, J. C. Gorga, R. G. Urban, J. L. Strominger, and D. C. Wiley. 1994. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature 368: 215.
15. d restricted determinants and T cell epitopes from the major bee venom allergen. Int. Immunol. 11:1313.
16. Charron, D., R. Fauchet, E. Albert, J. Bodmer, A. Cambon-Thomsen, L. Degos, J. Hors, A. Piazza, and I. Schreuder. 1997. Genetic diversity of HLA, functional and medical Implication. In XIIth International Histocompatibility Workshop and conference. D. Charron, ed. EDK, Paris, France, p. 669.
17. Sirigaglia, F., M. Guttinger, J. Kilgus, D. M. Doran, H. Matile, H. Etlinger, A. Trzeciak, D. Gillessen, and J. R. Pink. 1988. A malaria T-cell epitope recognized in association with most mouse and human MHC class II molecules. Nature 336:778.
18. Panina-Bordignon, P., A. Tan, A. Termijtelen, S. Demotz, G. Corradin, and A. Lanzavecchia. 1989. Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells. Eur. J. Immunol. 19:2237.
19. Alexander, J., J. Sidney, S. Southwood, J. Ruppert, C. Oseroff, A. Maewal, K. Snoke, H. M. Serra, R. T. Kubo, A. Sette, et al. 1994. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity 1:751.
20. O'Sullivan, D., T. Arrhenius, J. Sidney, M. F. Del Guercio, M. Albertson, M. Wall, C. Oseroff, S. Southwood, S. M. Colon, F. C. Gaeta, et al. 1991. On the interaction of promiscuous antigenic peptides with different DR alleles. Identification of common structural motifs. J. Immunol. 147:2663.
21. Hammer, J., P. Valsasnini, K. Tolba, D. Bolin, J. Higelin, B. Takacs, and F. Sinigaglia. 1993. Promiscuous and allele-specific anchors in HLA-DR-binding peptides. Cell 74:197.
22. Southwood, S., J. Sidney, A. Kondo, M. F. del Guercio, E. Appella, S. Hoffman, R. T. Kubo, R. W. Chesnut, H. M. Grey, and A. Sette. 1998. Several common HLA-DR types share largely overlapping peptide binding repertoires. J. Immunol. 160:3363.
23. Muller, U., A. Helbling, and E. Berchtold. 1992. Immunotherapy with honeybee venom and yellow jacket venom is different regarding efficacy and safety. J. Allergy Clin. Immunol. 89:529.
24. 2: the major bee-venom allergen. J. Allergy Clin. Immunol. 90:42.
25. 2 from honeybee venom glands: the deduced amino acid sequence reveals homology to the corresponding vertebrate enzymes. Eur. J. Biochem. 184:249.
26. Gorga, J. C., V. Horejsi, D. R. Johnson, R. Raghupathy, and J. L. Strominger. 1987. Purification and characterization of class II histocompatibility antigens from a homozygous human B cell line. J. Biol. Chem. 262:16087.
27. Colombani, J. 1993. HLA: Fonctions Immunitaires at Applications Médicales. John Libbey Eurotext, Montrouge, France.
28. Marshall, K. W., A. F. Liu, J. Canales, B. Perahia, B. Jorgensen, R. D. Gantzos, B. Aguilar, B. Devaux, and J. B. Rothbard. 1994. Role of the polymorphic residues in HLA-DR molecules in allele-specific binding of peptide ligands. J. Immunol. 152:4946.
29. Roche, P. A., and P. Cresswell. 1990. High-affinity binding of an influenza hemagglutinin-derived peptide to purified HLA-DR. J. Immunol. 144:1849.
30. Posch, P. E., A. E. Hastings, S. Rosen-Bronson, J. R. Richert, and C. K. Hurley. 1996. The relative importance of individual DR binding motif positions as defined by peptide anchor analysis of influenza hemagglutinin peptide 306-318 and human myelin basic protein peptide 152-165 binding to several DR molecules: definition of a common extended DR binding motif. Eur. J. Immunol. 26:1884.
31. Vogt, A. B., H. Kropshofer, H. Kalbacher, M. Kalbus, H. G. Rammensee, J. E. Coligan, and R. Martin. 1994. Ligand motifs of HLA-DRB5*0101 and DRB1*1501 molecules delineated from self-peptides. J. Immunol. 153:1665.
32. Davenport, M. P., C. L. Quinn, R. M. Chicz, B. N. Green, A. C. Willis, W. S. Lane, J. I. Bell, and A. V. Hill. 1995. Naturally processed peptides from two disease-resistance-associated HLA-DR13 alleles show related sequence motifs and Ihe effects of the dimorphism at position 86 of the HLA-DR beta chain. Proc. Natl. Acad. Sci. USA 92:6567.
33. Geluk, A., W. Bloemhoff, R. R. De Vries, and T. H. Ottenhoff. 1992. Binding of a major T cell epitope of mycobacteria to a specific pocket within HLA-DRw17(DR3) molecules. Eur. J. Immunol. 22:107.
34. Chicz, R. M., R. G. Urban, W. S. Lane, J. C. Gorga, L. J. Stern, D. A. Vignali, and J. L. Strominger. 1992. Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogeneous in size. Nature 358:764.
35. Geluk, A., V. Taneja, K. E. van Meijgaarden, E. Zanelli, C. Abou-Zeid, J. E. R. Thole, R. R. de Vries, C. S. David, and T. H. Ottenhoff. 1998. Identification of HLA class II-restricted determinants of mycobacterium tuberculosis-derived proteins by using HLA-transgenic, class II-deficient mice. Proc. Natl. Acad. Sci. USA 95:10797.
36. Malcherek, G., V. Gnau, S. Stevanovic, H. G. Rammensee, G. Jung, and A. Melms. 1994. Analysis of allele-specific contact sites of natural HLA-DR17 ligands. J. Immunol. 153:1141.
37. 2-specific T cell clones from human allergic and non-allergic individuals: cytokine patterns change in response to the antigen concentration. Eur. J. Immunol. 22:1357.
38. Newton-Nash, D. K., and D. D. Eckels. 1993. Differential effect of polymorphism at HLA-DR1 β-chain positions 85 and 86 on binding and recognition of DR1-restricted antigenic peptides. J. Immunol. 150:1813.
39. Verreck, F. A., A. Termijtelen, and F. Koning. 1993. HLA-DR beta chain residue 86 controls DR αβ dimer stability. Eur. J. Immunol. 23:1346.
40. Hammer, J., E. Bono, F. Gallazzi, C. Belunis, Z. Nagy, and F. Sinigaglia. 1994. Precise prediction of major histocompatibility complex class II-peptide interaction based on peptide side chain scanning. J. Exp. Med. 180:2353.
41. Marshall. K. W., K. J. Wilson, J. Liang, A. Woods, D. Zaller, and J. B. Rothbard. 1995. Prediction of peptide affinity to HLA DRB1*0401. J. Immunol. 154:5927.
42. Geluk, A., K. E. van Meijgaarden, S. Southwood, C. Oseroff, J. W. Drijfhout, R. R. de Vries, T. H. Ottenhoff, and A. Sette. 1994. HLA-DR3 molecules can bind peptides carrying two alternative specific submotifs. J. Immunol. 152:5742.
43. Faux, J. A., M. F. Moffatt, A. Lalvani, J. Dekker, D. A. Warrell, and W. O. Cookson. 1997. Sensitivity to bee and wasp venoms: association with specific IgE responses to the bee and wasp venom and HLA DRB1 and DPB1, Clin. Exp. Allergy 27:578.
44. Lympany, P., D. M. Kemeny, K. I. Welsh, and T. H. Lee. 1990. An HLA-associated nonresponsiveness to mellitin: a component of bee venom. J. Allergy Clin. Immunol. 86:160.